The Web's Daily Resource for PF News| Pulmonary Fibrosis News
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data presented by the therapy’s developer, Boehringer Ingelheim. “The new pooled data zoom in on nerandomilast’s potential as monotherapy, pairing efficacy with […] The post Nerandomilast appears to reduce risk of death in IPF, PPF: trial data appeared first o...| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
My journey to a diagnosis of idiopathic pulmonary fibrosis (IPF) began in the fall of 2016, when I was 59. It all started with a persistent cough. While the cough was annoying, especially to my wife, Susan, it wasn’t limiting my day-to-day activities. After seeing a radiologist’s report, my primary care physician of more than […] The post My IPF diagnostic journey began with a cough that wouldn’t go away appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
In 2009, I was at a point in my career in cardiology where I’d helped save many lives. I could spell both “pulmonary” and “fibrosis” because of some early transcription work I’d done, but I didn’t know much about pulmonary fibrosis (PF). I was quickly introduced to it when my late husband, Steve, was diagnosed that […] The post Living fully after my late husband’s pulmonary fibrosis diagnosis appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation and scarring in experiments done on lung tissue collected from IPF patients, according to a study. The study showed that LTI-03’s effects on inflammation and scarring were similar to those of the approved IPF treatment Ofev […] The post LTI-03 reduces inflammation, scarring in IPF lung samples: Study appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.| Pulmonary Fibrosis News
Trevi Therapeutics plans to launch two Phase 2 clinical trials testing Haduvio for chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with chronic cough.| Pulmonary Fibrosis News
A Phase 2b clinical trial testing Haduvio for IPF cough reached 75% of targeted enrollment but is still recruiting patients in 10 countries.| Pulmonary Fibrosis News
No description.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. Forced vital capacity (FVC), a measure of how much air a person can forcibly exhale, didn’t worsen during the first six weeks of the clinical trial (NCT06331624). The company recently […] The post Experimental oral therapy GRI-0621 may stabilize lung function in IPF appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
I’m at it again; I’m job hunting, or seeking employment, if you will. But this time, the search carries more weight. It’s not just about finding work; it’s about reclaiming a part of myself that I thought I’d lost. Teaching has always been my passion, the steady flame that keeps me going. And now, after […] The post Rediscovering who I am, then and now, in returning to teaching appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
There will be times when, despite everything you cover in planning for a trip, something happens that you didn’t anticipate. I can guarantee it. I shared with you my vacation details and preparations in my Aug. 26 column, all made to ensure the entire trip would be an opportunity to relax and recharge. But barely […] The post Oops! Planning my vacation, I didn’t think of everything. appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Using a specialized lab technique, a collaborative U.S. research team identified cellular changes in the body that could be early drivers of lung scarring (fibrosis) in people with pulmonary fibrosis (PF). That’s according to the findings of a new study in which the researchers, from three universities, exposed lung tissue to blue light. The scientists […] The post Specialized lab technique helps ID early drivers of lung scarring in PF appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.| Pulmonary Fibrosis News
September is Pulmonary Fibrosis Awareness Month, and advocates are hoping to call attention to the condition and interstitial lung diseases.| Pulmonary Fibrosis News
Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.| Pulmonary Fibrosis News
There are more immune NK T-cells in the lungs of people with idiopathic pulmonary fibrosis than in healthy people, research shows| Pulmonary Fibrosis News
Margarida Maia is a science writer for Pulmonary Fibrosis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Columnist Sam Kirton finds that filling the silence is part of living with a chronic condition, especially amid retirement and COVID-19.| Pulmonary Fibrosis News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Nuformix received a notice of allowance from the U.S. Patent Office, and awaits a patent for NXP002, an inhaled form of tranilast for IPF.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Vanda Pinto is a science writer for Pulmonary Fibrosis News with a PhD in biomedicine. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Columnist Ann Reynoso explains that she's using Ozempic to manage several health issues, but also to hopefully qualify for a lung transplant.| Pulmonary Fibrosis News
While columnist Sam Kirton's quality of life improved after his lung transplant, the healing journey hasn't been easy, he says.| Pulmonary Fibrosis News
Looking for information about pulmonary rehabilitation for pulmonary fibrosis (PF)? Read about it here.| Pulmonary Fibrosis News
Learn more about the signs, symptoms and complications associated with the debilitating respiratory disease pulmonary fibrosis.| Pulmonary Fibrosis News
Learn more about the tests and examinations used to reach a diagnosis of pulmonary fibrosis, which is characterized by scarring in the lungs.| Pulmonary Fibrosis News
Read about the different factors that can cause pulmonary fibrosis.| Pulmonary Fibrosis News
Pulmonary fibrosis is taxing for patients and family. Palliative care aims to help patients live longer and better lives through treatment and assistance.| Pulmonary Fibrosis News
Learn more about Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF).| Pulmonary Fibrosis News
Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.| Pulmonary Fibrosis News
Learn about familial pulmonary fibrosis, a rare form of pulmonary fibrosis, including its symptoms, diagnosis, risk factors, and treatment.| Pulmonary Fibrosis News
Esbriet (pirfenidone) is an oral treatment that has been approved by the U.S. Food and Drug Administration for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
Because certain IPF and post-transplant medications can cause sun sensitivity, skin protection is crucial, says columnist Sam Kirton.| Pulmonary Fibrosis News
A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary fibrosis.| Pulmonary Fibrosis News
During the dog days of summer, columnist Sam Kirton takes special care to protect himself from medication side effects.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Category archive page for Columns.| Pulmonary Fibrosis News
Columnist Ann Reynoso says she's struggling to lose weight, but each step forward, no matter how small, is still progress.| Pulmonary Fibrosis News
Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.| Pulmonary Fibrosis News